Sotagliflozin Cuts MACE Rate in Patients With T2DM, CKD, CVD Risk Factors

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 3, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, March 3, 2025 -- For patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors, the dual sodium-glucose co-transporter (SGLT)-1/2 inhibitor sotagliflozin is associated with a significantly reduced rate of major adverse cardiovascular events (MACE), with independent reductions in myocardial infarction and stroke, according to a study published online Feb. 14 in The Lancet Diabetes & Endocrinology.

Rahul Aggarwal, M.D., from Harvard Medical School in Boston, and colleagues conducted a prespecified secondary analysis of the SCORED trial, a double-blind, randomized trial enrolling adult patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors. A total of 10,584 patients from 750 sites in 44 countries were randomly assigned to receive oral sotagliflozin or placebo (5,292 to each group) between Dec. 8, 2017, and Jan. 20, 2020.

The researchers found that the rate of total MACE was significantly lower in the sotagliflozin group versus placebo group (4.8 versus 6.3 events per 100 person-years; hazard ratio [HR], 0.77). Among stratified subgroups, there was a consistent effect for sotagliflozin on total MACE, with no evidence of heterogeneity. Compared with placebo, sotagliflozin also significantly reduced the rate of myocardial infarction (1.8 versus 2.7 events per 100 person-years; HR, 0.68) and stroke (1.2 versus 1.8 events per 100 person-years; HR, 0.66).

"This ischemic benefit of sotagliflozin on both stroke and myocardial infarction has not been observed in trials of selective SGLT-2 inhibitors, warranting further investigation of SGLT-1 inhibition as a potential mechanism for these effects," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Lexicon Pharmaceuticals, which manufactures sotagliflozin and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-04 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords